Geriatric Medicine, Palliative & End-of-Life Care, Physical Medicine & Rehabilitation (PM&R) & Sleep Medicine

Age-related pharmacokinetic shifts—decreased Total Body Water (reducing Volume of Distribution Vd for hydrophilic drugs like lithium, digoxin, etanol, and aminoglycosides, leading to toxic peak serum levels), increased Body Fat percentage (increasing Vd and prolonging elimination half-life for lipophilic drugs like diazepam and trazodone), decreased serum albumin (increasing free unbound fraction of acidic drugs like phenytoin and warfarin), and reduced renal/Phase I hepatic clearance—render older adults exquisitely vulnerable to polypharmacy. The American Geriatrics Society (AGS) Beers Criteria catalog Potentially Inappropriate Medications (PIMs) whose risks outweigh benefits in older adults: (1) Strongly Anticholinergic Medications (1st-generation antihistamines [diphenhydramine, hydroxyzine, chlorpheniramine], tertiary amine tricyclic antidepressants [amitriptyline, doxepin, imipramine], bladder antimuscarinics [oxybutynin, tolterodine], and skeletal muscle relaxants [cyclobenzaprine]): block central M1 muscarinic receptors in the basal forebrain to precipitate acute Delirium, cognitive decline, blurred vision, dry mouth, constipation, and acute urinary retention (especially in men with BPH); (2) Benzodiazepines and Non-Benzodiazepine Z-Hypnotics (alprazolam, diazepam, zolpidem, eszopiclone): double the risk of hip fractures, falls, motor vehicle collisions, and paradoxical agitation/delirium; (3) Sulfonylureas (especially long-acting glyburide and chlorpropamide) and Sliding-Scale Insulin alone: cause prolonged, fatal neuroglycopenic hypoglycemia and SIADH; (4) Chronic NSAIDs (ibuprofen, naproxen, ketorolac, indomethacin): cause peptic ulcer perforation/bleeding, afferent arteriolar constriction AKI, fluid retention heart failure exacerbation, and hypertension; (5) Peripheral Alpha-1 Blockers (doxazosin, prazosin, terazosin for hypertension): cause severe orthostatic hypotension and syncope; and (6) Antipsychotics (haloperidol, risperidone, olanzapine, quetiapine) for behavioral symptoms of dementia: carry an FDA Boxed Warning for increased all-cause mortality (1.6–1.7x) from cerebrovascular strokes and sudden cardiac death.

Board vignettes also test recognition of 'Prescribing Cascades,' in which an adverse drug effect is misdiagnosed as a new medical condition and treated with a second unnecessary medication: classic examples include starting a cholinesterase inhibitor (donepezil, rivastigmine) for Alzheimer dementia to cholinergic stimulation of detrusor muscle causes urinary incontinence to clinician mistakenly adds an antimuscarinic (oxybutynin), which directly antagonizes donepezil in the brain and precipitates acute delirium! Another classic cascade is prescribing a dihydropyridine calcium channel blocker (amlodipine) to precapillary vasodilation causes ankle edema to clinician mistakenly adds furosemide to volume depletion, falls, and urinary incontinence; or prescribing metoclopramide to D2 blockade causes drug-induced parkinsonism (bradykinesia, resting tremor) to clinician mistakenly starts carbidopa-levodopa!

Unintentional falls are the leading cause of fatal and nonfatal traumatic injury (subdural hematoma, femoral neck/intertrochanteric hip fracture) in adults greater than or equal to 65 years old. Evidence-based geriatric fall prevention requires a Multifactorial Intervention: (1) Medication reconciliation and deprescribing psychotropics, sedatives, anticholinergics, and alpha-blockers; (2) Orthostatic vital signs (defined as a drop in SBP greater than or equal to 20 mmHg or DBP greater than or equal to 10 mmHg within 3 minutes of standing) and hydration/compression stockings; (3) Physical therapy with balance, gait, and lower-extremity progressive resistance training or Tai Chi (USPSTF Grade B recommendation!) and proper assistive device fitting (a cane is held in the hand CONTRALATERAL to the weak or painful hip/knee, with the handle at the level of the greater trochanter yielding 15–30 degrees of elbow flexion, advancing simultaneously with the affected leg!); (4) Home safety modification (removing throw rugs, installing bathroom grab bars, improving night lighting, and correcting visual acuity/cataracts); and (5) Osteoporosis DEXA screening and treatment. In immobilized or hospitalized older adults, prolonged tissue compression (greater than 32 mmHg capillary closing pressure) over bony prominences (sacrum, ischial tuberosities, greater trochanters, calcaneal heels) causes ischemic Pressure Injuries (Decubitus Ulcers), staged by anatomical depth: Stage 1 is intact skin with non-blanchable erythema (managed with repositioning every 2 hours, foam/air-fluidized pressure-redistributing mattresses, and barrier creams); Stage 2 is partial-thickness skin loss with exposed pink/red viable dermis or an intact/ruptured serum-filled blister (NO slough or granulation tissue; managed with moist hydrocolloid or foam dressings); Stage 3 is full-thickness skin loss extending into subcutaneous adipose tissue where granulation tissue, rolled epibole edges, undermining, or slough may be present, but fascia, muscle, tendon, and bone are NOT exposed; Stage 4 is full-thickness tissue loss with directly exposed or palpable bone, tendon, muscle, or joint capsule (high risk of contiguous polymicrobial osteomyelitis requiring MRI or bone biopsy and surgical flap debridement); Unstageable is full-thickness tissue loss completely obscured by yellow/tan slough or black/brown necrotic eschar (require sharp debridement to reveal the base before staging, EXCEPT stable, dry, intact heel eschars in ischemic limbs, which serve as a biological cover and should NOT be debrided!); and Deep Tissue Pressure Injury is intact or non-intact skin with localized persistent non-blanchable deep red, maroon, or purple discoloration from shear forces at the bone-muscle interface.

Geriatric urinary incontinence isnever 'normal aging' and is classified into four treatable types: (1) Stress Incontinence (urethral hypermobility or intrinsic sphincter deficiency in multiparous women or post-prostatectomy men to leakage on coughing, sneezing, or laughing, positive bladder stress test, normal post-void residual [PVR less than 50 mL]; 1st-line: Kegel pelvic floor muscle exercises + weight loss; 2nd-line: mid-urethral sling); (2) Urge Incontinence / Overactive Bladder (idiopathic or neurogenic detrusor overactivity to sudden uninhibitable urge to void with frequency and nocturia, normal PVR; 1st-line: bladder training drills + avoidance of caffeine/alcohol; 2nd-line: Beta-3 adrenergic agonist Mirabegron or Vibegron—preferred over antimuscarinics oxybutynin/solifenacin in older adults because mirabegron relaxes the detrusor without causing anticholinergic delirium or urinary retention!); (3) Overflow Incontinence (detrusor underactivity from diabetic autonomic neuropathy OR bladder outlet obstruction from BPH to continuous dribbling, weak stream, and HIGH post-void residual PVR greater than 200 mL; treated with intermittent catheterization, alpha-1 blocker tamsulosin for BPH, or bethanechol); and (4) Functional Incontinence (intact lower urinary tract, but physical mobility impairment [arthritis, restraints] or severe dementia prevents reaching the toilet in time; treated with scheduled prompted voiding every 2 hours and bedside commodes).

When a patient requires switching from one opioid to another (Opioid Rotation, due to inadequate analgesia despite dose escalation or intolerable neurotoxic side effects such as myoclonus), clinicians use the standard Equianalgesic Conversion Ratios (memorized relative to 30 mg of Oral Morphine): 30 mg Oral Morphine = 10 mg IV/SC Morphine (3:1 oral-to-parenteral ratio due to hepatic first-pass glucuronidation) = 20 mg Oral Oxycodone = 7.5 mg Oral Hydromorphone = 1.5 mg IV/SC Hydromorphone (5:1 ratio) = 30 mg Oral Hydrocodone. Because patients develop Incomplete Cross-Tolerance between different mu-opioid receptor agonists, the calculated equianalgesic 24-hour dose of the new opioid MUST be reduced by 25 to 50 percent before initiation (unless the patient's pain was severely uncontrolled at the time of rotation, in which case a smaller 0–25 percent reduction plus breakthrough rescue dosing is used). Let us walk through a classic board calculation: A patient taking 60 mg of Oral Morphine every 12 hours (total = 120 mg/day Oral Morphine) develops renal insufficiency and needs conversion to IV Hydromorphone with a 25 percent cross-tolerance reduction to Since 30 mg Oral Morphine = 1.5 mg IV Hydromorphone (20:1 ratio), 120 mg Oral Morphine equals 6.0 mg/day IV Hydromorphone to Reducing 6.0 mg by 25 percent yields 4.5 mg/day IV Hydromorphone (administered as 0.75 mg IV every 4 hours).

Organ dysfunction dictates strict opioid selection in palliative and critical care: Morphine is metabolized by hepatic UGT2B7 into two active glucuronide metabolites—Morphine-3-Glucuronide (M3G, which has zero analgesic activity but causes central neuroexcitation, delirium, agitation, allodynia/hyperalgesia, and prominent multifocal Myoclonus) and Morphine-6-Glucuronide (M6G, which is a more potent mu-agonist than morphine itself and causes profound sedation and respiratory depression). Both M3G and M6G (as well as active metabolites of Codeine, Tramadol, and Meperidine's normeperidine, which causes seizures) are excreted strictly by the kidneys and accumulate rapidly in Acute Kidney Injury or Chronic Kidney Disease (GFR less than 30 mL/min)! Therefore, in patients with renal failure (CKD Stage 4–5 or ESRD), Morphine, Codeine, Tramadol, and Meperidine are CONTRAINDICATED; the safest opioids in severe renal failure are Fentanyl and Methadone (which lack active renally cleared metabolites), followed by Hydromorphone with cautious dose reduction.

Comprehensive end-of-life care targets four cardinal non-pain symptom complexes: (1) Refractory Dyspnea and Air Hunger (in terminal COPD, idiopathic pulmonary fibrosis, heart failure, or lymphangitic carcinomatosis): Low-dose Systemic Opioids (oral or intravenous morphine or hydromorphone) are the FIRST-LINE evidence-based pharmacotherapy for refractory dyspnea at the end of life (opioids blunt medullary chemoreceptor sensitivity to hypercapnia/hypoxia, decrease the work of breathing, and reduce cortical perception of air hunger WITHOUT hastening death when titrated to symptom relief; accompany with a handheld cool-air fan directed at the cheek [trigeminal CN V2 cooling reflex reduces dyspnea] and supplemental oxygen ONLY if the patient is hypoxemic). (2) Terminal Respiratory Secretions ('Death Rattle' in the final hours to days of life as the obtunded patient loses the ability to swallow pooling oropharyngeal saliva): Reassure the family that the noisy gurgling reflects air moving past pooled pharyngeal secretions and does NOT cause the patient choking distress; reposition the patient into a lateral decubitus posture, avoid deep pharyngeal suctioning (which triggers gagging and mucosal trauma), discontinue unnecessary IV fluids, and administer an antimuscarinic drying agent—preferably Glycopyrrolate (quaternary amine that does NOT cross the blood-brain barrier and therefore avoids central delirium!), Hyoscyamine, Atropine sublingual drops, or transdermal Scopolamine.

(3) Inoperable Malignant Bowel Obstruction (peritoneal carcinomatosis from ovarian or colon cancer causing multifocal mechanical obstruction where surgery or stenting is not feasible): Manage medically by discontinuing prokinetic agents (metoclopramide is CONTRAINDICATED in complete mechanical bowel obstruction because increasing peristalsis against a closed lumen causes colicky pain and bowel perforation!) and administering a triad of Octreotide (synthetic somatostatin analog that potently reduces gastrointestinal and pancreatic exocrine fluid secretion and splanchnic blood flow), Dexamethasone (reduces peritumoral inflammatory bowel wall edema to restore partial luminal patency and acts as a central antiemetic), and Haloperidol or Olanzapine (dopamine D2 antagonists at the area postrema chemoreceptor trigger zone for nausea) plus parenteral opioids for pain. (4) Cancer Cachexia and End-of-Life Anorexia: Driven by tumor cytokines (TNF-alpha, IL-1, IL-6, IFN-gamma) inducing proteolysis and lipolysis; crucially, in patients with advanced dementia or terminal cancer at the end of life, percutaneous endoscopic gastrostomy (PEG) feeding tubes and total parenteral nutrition (TPN) do NOT prolong survival, do NOT prevent aspiration pneumonia, do NOT heal pressure ulcers, and increase fluid overload and physical restraint use—counsel families empathetically to use careful hand-feeding for comfort and moist oral swabs for xerostomia (if short-term appetite stimulation is desired in a patient with weeks-to-months prognosis, dexamethasone or megestrol acetate—noting thromboembolic risk—or mirtazapine may be used).

Autonomic Dysreflexia is a life-threatening neuro-hypertensive emergency that occurs exclusively in patients with a spinal cord injury at or ABOVE the T6 thoracic segment (after spinal shock has resolved), because the Greater Splanchnic Nerve (T5–T9) controls the massive capacitance vascular bed of the abdominal splanchnic circulation. When a noxious visceral or cutaneous stimulus occurs BELOW the level of the spinal cord lesion—most commonly (#1) Urinary Bladder Distension (kinked/obstructed Foley catheter, urinary retention, urinary tract infection, bladder stones, or urodynamic testing) or (#2) Fecal Impaction / Rectal Distension (followed by pressure ulcers, ingrown toenails, tight clothing/leg bag straps, fractures, or labor contractions)—nociceptive afferents enter the dorsal horn of the caudal spinal cord and trigger a massive, uninhibited sympathetic reflex surge across the thoracolumbar splanchnic outflow (T5–L2), causing extreme splanchnic and lower-extremity vasoconstriction and malignant paroxysmal Hypertension (systolic BP often surging greater than 200–260 mmHg, risking hemorrhagic stroke, retinal hemorrhage, myocardial infarction, and pulmonary edema).

Intact carotid sinus and aortic arch baroreceptors sense the acute hypertensive crisis and relay signals via CN IX and CN X to the brainstem medulla, which responds via two pathways: (1) The medulla fires strong parasympathetic Vagus nerve (CN X) signals to the SA node, causing reflex Bradycardia (though tachycardia can occasionally occur); and (2) The medulla attempts to send descending inhibitory vasomotor signals down the spinal cord to dilate the splanchnic bed, but these inhibitory signals are BLOCKED at the T6-or-higher spinal cord transected lesion! Consequently, above the level of the spinal cord injury (head, neck, and shoulders), intact parasympathetic/vasodilatory outflow causes pounding throbbing headache, profuse diaphoresis, flushing, nasal congestion, and blurred vision, while below the lesion, unopposed sympathetic tone causes pale, cold, piloerection skin. The Mandatory Step-by-Step Emergency Management Algorithm for Autonomic Dysreflexia is tested heavily on COMLEX and USMLE: Step 1 (FIRST action!): Immediately sit the patient UPRIGHT (90 degrees) and dangle the legs over the side of the bed (utilizes orthostatic hydrostatic pooling in the lower extremities to immediately drop blood pressure by 20–30 mmHg!); Step 2: Loosen all tight clothing, abdominal binders, compression stockings, and leg-bag straps; Step 3: Check the urinary bladder FIRST—if an indwelling Foley catheter is present, inspect for kinks and irrigate/replace it immediately; if no catheter is present, perform straight catheterization (instilling 2 percent lidocaine jelly into the urethra 2–3 minutes prior to catheterization to prevent worsening the afferent trigger!); Step 4: If blood pressure remains elevated after bladder decompression, check the rectum for Fecal Impaction (instill topical 2 percent lidocaine jelly into the rectum for 5 minutes BEFORE performing gentle digital disimpaction!); and Step 5: If systolic BP remains greater than or equal to 150 mmHg despite sitting upright and removing bladder/bowel triggers (or prior to digital disimpaction), administer a rapid-onset, short-acting antihypertensive agent—Topical 2 percent Nitroglycerin paste (applied to the chest above the lesion so it can be wiped off once the trigger is relieved!), sublingual Captopril, immediate-release Nifedipine, or IV Hydralazine/Nicardipine.

Heterotopic Ossification (HO) is the pathological formation of mature, vascularized lamellar bone within periarticular soft tissues and skeletal muscle planes (most commonly around the HIP [anterior/abductor compartment] after spinal cord injury or traumatic brain injury, and around the ELBOW after burns or fractures) beginning 2 to 12 weeks post-injury. Pluripotent mesenchymal stem cells undergo inappropriate osteoblastic differentiation driven by bone morphogenetic proteins (BMPs) and local neurogenic inflammation. Clinically, HO presents as localized periarticular pain, warmth, erythema, firm non-pitting swelling, low-grade fever, and progressive loss of joint range of motion—closely mimicking deep vein thrombosis, septic arthritis, or cellulitis! Laboratory evaluation reveals a markedly elevated serum Alkaline Phosphatase (reflecting active osteoblast bone matrix synthesis) with normal serum calcium and phosphorus. Crucially, plain radiographs remain NORMAL for the first 2–4 weeks until calcium hydroxyapatite mineralizes; the most sensitive test for EARLY diagnosis (within week 1–2) is a Triple-Phase Technetium-99m Bone Scan (showing intense increased uptake in the blood-flow, blood-pool, and delayed osteoblastic phases) or bedside ultrasound. Management consists of gentle passive range-of-motion physical therapy to preserve functional joint angles, Indomethacin (or selective COX-2 inhibitors / single-fraction radiation therapy for prophylaxis and early arrest of osteoblast differentiation), and delaying surgical excision until the heterotopic bone is fully mature (6–18 months post-injury, confirmed by normalization of serum alkaline phosphatase and quiescent bone scan uptake, to prevent massive recurrence!).

Neurogenic Bladder Dysfunction depends on the anatomical site of injury relative to the Pontine Micturition Center (PMC) and Sacral Micturition Center (S2–S4): (1) Suprapontine Lesions (cortical stroke, Parkinson disease, normal pressure hydrocephalus, dementia) abolish frontal lobe inhibition of the PMC to Detrusor Hyperreflexia with coordinated sphincter relaxation to Urge Incontinence with small bladder capacity and LOW post-void residual (treated with timed voiding and mirabegron); (2) Suprasacral Spinal Cord Lesions (between the pons and S2: cervical/thoracic SCI or multiple sclerosis plaques) sever connection to the PMC to Detrusor-Sphincter Dyssynergia (the hyperreflexic detrusor contracts simultaneously against a spastically closed external urethral sphincter, generating dangerously high intravesical pressures greater than 40 cmH2O that cause vesicoureteral reflux, hydronephrosis, and renal failure; treated with Clean Intermittent Catheterization every 4–6 hours PLUS oral oxybutynin/mirabegron or intradetrusor OnabotulinumtoxinA injections to keep bladder storage pressure low!); and (3) Sacral / Infrasacral Lesions (conus medullaris/cauda equina syndrome, pelvic surgery, or diabetic autonomic neuropathy affecting S2–S4) destroy the lower motor neurons of the pelvic nerves to Areflexic Flaccid Bladder with high compliance and overflow incontinence (HIGH PVR greater than 300 mL; treated with Clean Intermittent Catheterization). For generalized upper motor neuron Spasticity interfering with positioning, hygiene, or gait, first-line oral agents are Baclofen (a GABA-B receptor agonist in the spinal cord dorsal horn that inhibits monosynaptic and polysynaptic excitatory neurotransmitter release; abrupt withdrawal of intrathecal baclofen causes a life-threatening hyperthermic rebound storm with rhabdomyolysis and status epilepticus!) and Tizanidine (a central alpha-2 adrenergic agonist, similar to clonidine, that causes dry mouth, sedation, and hypotension—and is contraindicated with ciprofloxacin or fluvoxamine due to CYP1A2 inhibition!), whereas focal limb spasticity (e.g., post-stroke clenched fist or equinovarus foot) is treated first-line with targeted intramuscular Botulinum Toxin A injections.

REM (Paradoxical) Sleep accounts for 20–25 percent of total sleep time, lengthens progressively during the second half of the night (occurring every 90 minutes), and is driven by cholinergic neurons in the mesopontine tegmentum (pedunculopontine and laterodorsal tegmental nuclei: 'REM sleep is turned ON by Acetylcholine and turned OFF by Norepinephrine and Serotonin' from the locus coeruleus and dorsal raphe!). On Polysomnography, REM sleep exhibits desynchronized low-voltage, mixed-frequency Beta and Theta waves with characteristic 'Sawtooth Waves' (hence 'paradoxical sleep,' because the EEG resembles an awake, active brain with increased cerebral O2 consumption!), accompanied by phasic Rapid Eye Movements, vivid narrative dreaming (unlike N3 sleep terrors, patients awakened from a REM Nightmare are immediately alert and recall the frightening dream in vivid detail!), variable autonomic heart rate/blood pressure fluctuations, nocturnal penile/clitoral tumescence (preserved nocturnal erections in REM sleep confirm psychogenic rather than organic vascular/neurogenic erectile dysfunction!), and profound Skeletal Muscle Atonia (descending glutamatergic/glycinergic/GABAergic projections from the sublaterodorsal nucleus paralyze spinal alpha-motor neurons, sparing ONLY the extraocular muscles and the diaphragm!).

In REM Sleep Behavior Disorder (RBD), brainstem neurodegeneration destroys the pontomedullary nuclei responsible for REM muscle atonia. Consequently, patients (characteristically older men greater than 50–60 yr) lose normal REM paralysis and physically act out violent, action-packed dreams (punching, kicking, leaping out of bed, or injuring their bed partner) during the second half of the night, and when awakened, vividly recall the dream matching their motor actions! Crucially, idiopathic REM Sleep Behavior Disorder is the strongest prodromal clinical biomarker of an underlying Alpha-Synucleinopathy—over 80 percent of patients with RBD convert within 10–15 years to Parkinson Disease, Dementia with Lewy Bodies, or Multiple System Atrophy! Management of RBD prioritizes bedroom safety (removing sharp nightstand objects, placing a mattress on the floor) and first-line pharmacotherapy with high-dose oral Melatonin at bedtime (preferred in older adults over low-dose Clonazepam due to clonazepam's fall and cognitive risks). Compare RBD with Restless Legs Syndrome (RLS / Willis-Ekbom Disease, a wakeful sensorimotor disorder driven by central nervous system iron deficiency impairing tyrosine hydroxylase dopamine synthesis in the nigrostriatal/spinal pathways, frequently accompanied by Periodic Limb Movements of Sleep during NREM sleep): RLS is diagnosed clinically by the URGE criteria—an uncomfortable creeping/crawling Urge to move the legs, precipitated by Rest/inactivity, relieved by Getting up and walking/stretching, and worsening in the Evening/night. Evaluation of RLS ALWAYS begins by checking a fasting serum Ferritin level (supplementing oral or IV iron whenever serum ferritin is less than or equal to 75 ng/mL or transferrin saturation less than 20 percent!) and discontinuing triggers (antihistamines, SSRIs/SNRIs, metoclopramide, caffeine); first-line daily pharmacotherapy is an alpha-2-delta calcium channel ligand (Gabapentin enacarbil or Pregabalin), which is now preferred over dopamine agonists (pramipexole, ropinirole) because chronic dopamine agonists cause 'Augmentation' (paradoxical earlier daytime onset and anatomic spread of symptoms).

Sleep-Disordered Breathing is diagnosed by nocturnal Polysomnography (or Home Sleep Apnea Testing in uncomplicated high-probability OSA) using the Apnea-Hypopnea Index (AHI = total apneas [greater than or equal to 10-second cessation of airflow] plus hypopneas [greater than or equal to 10-second greater than or equal to 30 percent airflow reduction with greater than or equal to 3–4 percent O2 desaturation] per hour of sleep; AHI greater than or equal to 5/hr with symptoms or greater than or equal to 15/hr regardless of symptoms confirms diagnosis). Polysomnography distinguishes Obstructive from Central Sleep Apnea by inspecting the thoracoabdominal respiratory effort belts during the 10-second cessation of nasal airflow: (1) Obstructive Sleep Apnea (OSA) is caused by repetitive pharyngeal soft-tissue collapse (genioglossus relaxation, obesity neck circumference greater than 17 in [men] or greater than 16 in [women], retrognathia, or pediatric adenotonsillar hypertrophy) against a closed upper airway to Nasal airflow is ABSENT, while thoracoabdominal respiratory effort belts show PERSISTENT, paradoxical thoracoabdominal excursions against the occluded pharynx until microarousal restores muscle tone (loud snoring, witnessed gasping/choking, morning headaches from nocturnal hypercapnia cerebral vasodilation, daytime hypersomnolence, systemic hypertension, atrial fibrillation, pulmonary hypertension, and secondary erythrocytosis/polycythemia from nocturnal EPO surges). First-line treatment for adult OSA is Continuous Positive Airway Pressure (CPAP, which acts as a pneumatic splint to stent the velopharynx open) plus weight loss, lateral positional therapy, and avoidance of alcohol/sedatives (or custom mandibular advancement oral appliances in mild-to-moderate OSA; in children, first-line treatment is Adenotonsillectomy!).

(2) Central Sleep Apnea (CSA) is caused by transient cessation of medullary respiratory pacemaker drive to BOTH nasal airflow AND thoracoabdominal respiratory effort are simultaneously ABSENT during the apneic event! CSA occurs in two classic settings: (a) Cheyne-Stokes Respiration in Congestive Heart Failure (HFrEF) or Cortical Stroke (prolonged circulatory transit time delays feedback between alveolar gas changes and medullary chemoreceptors to crescendo-decrescendo hyperpnea alternating with central apnea; treated by optimizing heart failure guideline-directed medical therapy, CPAP, or nocturnal oxygen; note that Adaptive Servo-Ventilation [ASV] is CONTRAINDICATED in HFrEF with LVEF less than or equal to 45 percent due to increased cardiovascular mortality!) and (b) Opioid-Induced Central Sleep Apnea (mu-opioid suppression of the pre-Botzinger complex to ataxic Biot breathing; treated by opioid dose reduction or Bilevel PAP with a backup respiratory rate). Finally, Obesity Hypoventilation Syndrome (OHS / Pickwickian Syndrome) is defined by the triad of Morbid Obesity (BMI greater than or equal to 30 kg/m2), chronic DAYTIME Awakening Alveolar Hypoventilation (arterial PaCO2 greater than 45 mmHg and PaO2 less than 70 mmHg while awake, with compensatory renal metabolic alkalosis [serum HCO3- greater than or equal to 27 mEq/L]), and sleep-disordered breathing (90 percent have coexisting severe OSA) in the absence of COPD or neuromuscular disease—managed with nocturnal CPAP or noninvasive Bilevel Positive Airway Pressure (BiPAP) plus bariatric weight reduction.

Major Neurocognitive Disorder (Dementia) is characterized by insidious, progressive decline over months to years in one or more cognitive domains (memory, executive function, language, visuospatial perception, or social cognition) that interferes with independence in Instrumental and Basic Activities of Daily Living in a patient with a CLEAR sensorium and preserved baseline attention: (1) Alzheimer Disease (60–80 percent of cases; early insidious loss of anterograde episodic short-term memory due to entorhinal cortex and hippocampal CA1 atrophy, progressing to apraxia, aphasia, and visuospatial disorientation): Driven by extracellular beta-amyloid (Abeta42, cleaved from amyloid precursor protein encoded on Chromosome 21 by beta- and gamma-secretase; early-onset autosomal dominant familial AD involves Presenilin-1/2 or APP mutations, while late-onset sporadic AD is strongly linked to the APOE epsilon-4 allele, whereas APOE epsilon-2 is protective!) plaques (which also deposit in cerebral vessels to cause Cerebral Amyloid Angiopathy lobar hemorrhage) and intracellular hyperphosphorylated Tau neurofibrillary tangles, accompanied by loss of cholinergic neurons in the Nucleus Basalis of Meynert (treated symptomatically with acetylcholinesterase inhibitors Donepezil, Rivastigmine, or Galantamine + NMDA receptor antagonist Memantine for moderate-to-severe disease); (2) Vascular Neurocognitive Disorder (15–20 percent of cases): Presents with a classic 'stepwise deterioration' of executive function and processing speed with focal upper motor neuron neurological deficits (extensor plantar response, gait pseudobulbar affect) temporally linked to cortical strokes or confluent subcortical periventricular white-matter lacunar infarcts (Binswanger leukoaraiosis from chronic hypertension).

(3) Dementia with Lewy Bodies (DLB, intracellular alpha-synuclein eosinophilic Lewy body inclusions in cortical and substantia nigra neurons): Defined by fluctuating cognition, recurrent well-formed vivid Visual Hallucinations (seeing small animals or people in the room), REM Sleep Behavior Disorder, and spontaneous Parkinsonism occurring BEFORE or within 1 year of cognitive decline (remember the 1-Year Rule: in DLB, dementia begins before or within 1 year of parkinsonism; in Parkinson Disease Dementia, motor parkinsonism precedes dementia by more than 1 year!). Patients with DLB have extreme Neuroleptic Sensitivity—administering D2-blocking antipsychotics (haloperidol, risperidone) precipitates fatal rigidity and neuroleptic malignant syndrome! (4) Frontotemporal Dementia (Pick Disease: focal atrophy of the frontal and anterior temporal lobes ['knife-edge' gyri] with hyperphosphorylated Tau Pick bodies or TDP-43 inclusions in patients aged 45–65 yr): Presents early with profound behavioral disinhibition, apathy, hyperorality (compulsive binge-eating of sweets), loss of empathy, or Primary Progressive Aphasia while memory and visuospatial skills remain relatively spared initially! (5) Normal Pressure Hydrocephalus (NPH: impaired arachnoid granulation CSF absorption causing enlarged ventricles out of proportion to sulcal atrophy on MRI [Evans index greater than 0.3] with NORMAL lumbar puncture opening pressure): Presents with the classic reversible triad of 'Wet, Wobbly, and Wacky'—Gait Apraxia (magnetic, wide-based shuffling feet stuck to the floor, which appears FIRST and responds best to treatment!), Urinary Incontinence (detrusor overactivity), and subcortical Frontal Executive Dementia; confirmed via the high-volume Lumbar Tap Test (removing 30–50 mL of CSF produces rapid transient improvement in gait speed) and treated definitively with a Ventriculoperitoneal (VP) Shunt.

Late-Life Major Depressive Disorder frequently mimics dementia in older adults—a reversible clinical syndrome termed 'Pseudodementia' (Depressive Cognitive Dysfunction). On board exams, six clinical clues reliably separate Pseudodementia from true Alzheimer Dementia: (1) Onset in Pseudodementia is relatively subacute (weeks to months, often following bereavement, retirement, or medical illness) with a clear date of onset, whereas Alzheimer onset is insidious over years; (2) Patients with Pseudodementia are acutely distressed by and complain emphatically about their memory lapses ('I cannot remember anything!'), whereas patients with Alzheimer disease typically minimize, confabulate, or remain unaware of their cognitive deficits (anosognosia) while family members bring them to the clinic; (3) On cognitive testing (MMSE or Montreal Cognitive Assessment [MoCA]), patients with Pseudodementia display poor effort and frequently answer 'I don't know' to simple orientation/recall questions, whereas Alzheimer patients try hard but give incorrect answers; (4) Pseudodementia causes equal impairment of recent and remote memory without cortical aphasia or apraxia; (5) Nocturnal sleep in Pseudodementia shows early-morning terminal insomnia and shortened REM latency; and (6) Cognitive deficits in Pseudodementia resolve completely upon treatment of the underlying depression with a first-line SSRI (Sertraline or Escitalopram—avoiding paroxetine due to anticholinergic effects and avoiding fluoxetine due to long half-life!) or electroconvulsive therapy.

Every patient presenting with new-onset cognitive decline requires a targeted laboratory and neuroimaging workup to exclude reversible metabolic, infectious, and structural mimics of dementia: check a Complete Blood Count, Comprehensive Metabolic Panel (calcium, sodium, renal/hepatic function), Serum Vitamin B12 (cyanocobalamin deficiency causes reversible subacute combined degeneration and megaloblastic dementia) and Folate, Thyroid-Stimulating Hormone (TSH: hypothyroidism causes reversible cognitive slowing), and non-contrast Brain CT or MRI (to rule out chronic subdural hematoma, frontal meningioma, normal pressure hydrocephalus, or vascular strokes), plus RPR/Treponemal serology and HIV testing in patients with risk factors (and 14-3-3 protein / RT-QuIC CSF assay with periodic sharp wave complexes on EEG if rapidly progressive dementia with startle myoclonus over weeks-to-months suggests Creutzfeldt-Jakob Prion Disease!). Finally, always screen family caregivers of dementia patients for Caregiver Burnout and Elder Abuse/Neglect, connecting families early with adult day services, respite care, and durable power of attorney advance care planning while decision-making capacity is still intact.

Needle Electromyography (EMG) records electrical activity directly from skeletal muscle fibers at rest (insertional and spontaneous activity) and during voluntary contraction (Motor Unit Action Potential [MUAP] morphology and recruitment): (1) Normal Muscle at Rest is electrically silent after brief needle insertion. The presence of Spontaneous Fibrillation Potentials and Positive Sharp Waves at rest indicates active denervation (loss of axonal continuity with the muscle fiber, seen in radiculopathy, axonal neuropathy, ALS, or inflammatory myositis), whereas Fasciculation Potentials reflect spontaneous firing of an entire motor unit (classic in Anterior Horn Cell disease—Amyotrophic Lateral Sclerosis [ALS], which uniquely shows widespread acute denervation [fibrillations/positive sharp waves] AND chronic reinnervation [large polyphasic MUAPs] across three or more craniobulbar, cervical, thoracic, and lumbosacral regions with completely NORMAL sensory SNAPs!). (2) In Chronic Neuropathic Lesions (collateral sprouting of surviving axons reinnervating orphaned muscle fibers), voluntary contraction produces Giant, Long-Duration, High-Amplitude, Polyphasic MUAPs with Decreased (Reduced) Recruitment (fewer motor units firing rapidly); (3) Conversely, in Primary Myopathies (polymyositis, dermatomyositis, muscular dystrophy, steroid myopathy), random loss of individual muscle fibers within each motor unit shrinks the motor unit territory, producing Small, Short-Duration, Low-Amplitude, Polyphasic MUAPs with Early Recruitment (many motor units must be recruited immediately even to generate minimal force against gravity!).

Repetitive Nerve Stimulation (RNS) on electrodiagnostic testing distinguishes Postsynaptic from Presynaptic Neuromuscular Junction disorders: (1) Myasthenia Gravis (autoantibodies against postsynaptic nicotinic Acetylcholine Receptors [AChR, associated with thymoma/thymic hyperplasia] or Muscle-Specific Kinase [MuSK]): Slow repetitive nerve stimulation at 2–3 Hz rapidly depletes the immediately available presynaptic ACh vesicles, and because postsynaptic AChR safety factor is lost, fewer muscle fibers reach threshold—producing a characteristic DECREMENTAL response (progressive decrease in CMAP amplitude of greater than 10 percent by the 4th or 5th stimulation!), which improves after rest or edrophonium/pyridostigmine; and (2) Lambert-Eaton Myasthenic Syndrome (LEMS: paraneoplastic autoantibodies against presynaptic P/Q-type Voltage-Gated Calcium Channels in Small Cell Lung Cancer, presenting with proximal hip-girdle weakness, autonomic dry mouth/orthostasis, and hyporeflexia that IMPROVES with repeated muscle contraction!): Baseline single-stimulus CMAP amplitude is very low, and High-Frequency Repetitive Nerve Stimulation at 20–50 Hz (or 10 seconds of maximal isometric exercise) forces calcium accumulation inside the presynaptic terminal, triggering massive ACh exocytosis and a dramatic INCREMENTAL response (CMAP amplitude increases by greater than 60 to 100 percent!).

Comprehensive Post-Stroke Rehabilitation begins within 24–48 hours of acute ischemic or hemorrhagic stroke stabilization to leverage activity-dependent cortical neuroplasticity and prevent secondary immobilization complications: (1) Post-Stroke Dysphagia Screening: Every acute stroke patient MUST remain NPO until passing a bedside water-swallow screening test; patients who fail bedside screening (wet/gurgly voice, cough on swallowing, cranial nerve IX/X/XII deficits, or lateral medullary Wallenberg syndrome) require a Modified Barium Swallow Study (Videofluoroscopic Swallow Study—the gold standard!) or Fiberoptic Endoscopic Evaluation of Swallowing (FEES) to guide thickened-liquid diet modification and chin-tuck posture (if dysphagia persists beyond 1–2 weeks, transition from nasogastric tube to PEG tube); (2) Hemiplegic Shoulder Pain and Inferior Glenohumeral Subluxation: During the initial flaccid stage of post-stroke hemiplegia, paralysis of the supraspinatus and deltoid rotator cuff allows the weight of the unsupported arm to pull the humeral head inferiorly out of the glenoid fossa (producing a palpable sulcus sign); prevent and treat inferior shoulder subluxation by supporting the arm on a wheelchair lap tray or hemi-sling, using functional electrical stimulation to the supraspinatus/posterior deltoid, and STRICTLY forbidding staff from pulling on the hemiplegic arm during bed transfers (which causes rotator cuff tears, brachial plexus traction injury, and Complex Regional Pain Syndrome Type I ['Shoulder-Hand Syndrome']!). (3) Deep Vein Thrombosis Prophylaxis (subcutaneous enoxaparin or intermittent pneumatic compression sleeves in hemorrhagic stroke) and early depression screening (Post-Stroke Depression occurs in 30–50 percent of survivors, especially after left frontal lesions, and is treated first-line with SSRIs like sertraline, which also enhance motor recovery).

Lower-extremity Orthotics (Braces) and Lower-Limb Amputation Prosthetics are tested via biomechanical gait correlations: (1) Foot Drop (Steppage Gait: weakness of ankle dorsiflexion [tibialis anterior, L4–L5 deep fibular nerve] from common fibular nerve compression at the fibular neck, L5 radiculopathy, or stroke): Managed with an Ankle-Foot Orthosis (AFO), which holds the ankle in neutral 90-degree dorsiflexion during the swing phase to prevent toe drag and trips; note that in a stroke patient with spastic equinovarus foot drop PLUS knee hyperextension (genu recurvatum) during stance phase, setting the AFO in 5 degrees of slight dorsiflexion creates a knee-flexion moment that corrects genu recurvatum (whereas setting an AFO in excessive dorsiflexion causes knee buckling during heel strike!). (2) In Lower-Extremity Amputations (performed for ischemic peripheral arterial disease, diabetic gangrene, or trauma), preserving the knee joint in a Below-Knee (Transtibial) Amputation requires only a 10 to 25 percent increase in metabolic energy expenditure for ambulation (compared with a 65 to 100 percent energy increase in an Above-Knee [Transfemoral] Amputation, and 100–200 percent in bilateral amputations!). The #1 preventable mechanical barrier to fitting a below-knee prosthesis is a Knee Flexion Contracture (prevented by instructing the patient to lie prone for 30 minutes twice daily, keep the residual limb extended on a wheelchair board, and NEVER prop the residual stump up on a pillow under the knee!), while the #1 barrier in an above-knee amputation is a Hip Flexion and Abduction Contracture.